The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality

References

• Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• COVID-19 Data Explorer - Our World in Data. Available from: https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed May 9, 2023.
   Google Scholar
• Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19: equity-related analyses and update on evidence. Cochrane Database Sys Rev. 2022;2022:11.
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–374. doi:10.1007/s11427-020-1643-8
   PubMed Web of Science ®Google Scholar
• COVID-19 is more dangerous for older people and its severity is increasing: a case-control study - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/34677152/. Accessed May 9, 2023.
   Google Scholar
• Kosidło JW, Wolszczak-Biedrzycka B, Dymicka-Piekarska V, Dorf J, Matowicka-Karna J. Clinical Significance and Diagnostic Utility of NLR, LMR, PLR and SII in the Course of COVID-19: a Literature Review. J Inflamm Res. 2023;16:539–562. doi:10.2147/JIR.S395331
   PubMed Web of Science ®Google Scholar
• Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. 新型冠状病毒肺炎危重型患者心肌损伤及患有心血管基础疾病的情况分析 [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:567–571. doi:10.3760/cma.j.cn112148-20200225-00123
   PubMedGoogle Scholar
• Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409–1420. doi:10.1007/s00134-011-2261-x
   PubMed Web of Science ®Google Scholar
• Huyut MT, Huyut Z. Forecasting of Oxidant/Antioxidant levels of COVID-19 patients by using Expert models with biomarkers used in the Diagnosis/Prognosis of COVID-19. Int Immunopharmacol. 2021;100:108127. doi:10.1016/j.intimp.2021.108127
   PubMed Web of Science ®Google Scholar
• Tahir Huyut M, Huyut Z, İlkbahar F, Mertoğlu C. What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality? Int Immunopharmacol. 2022;105:108542.
   PubMed Web of Science ®Google Scholar
• Smail SW, Babaei E, Amin K. Hematological, Inflammatory, Coagulation, and Oxidative/Antioxidant Biomarkers as Predictors for Severity and Mortality in COVID-19: a Prospective Cohort-Study. Int J Gen Med. 2023;16:565–580. doi:10.2147/IJGM.S402206
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang J, Yang Y, et al. The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020;12. doi:10.15252/emmm.202012421
   Web of Science ®Google Scholar
• Huyut MT, Velichko A, Belyaev M. Detection of Risk Predictors of COVID-19 Mortality with Classifier Machine Learning Models Operated with Routine Laboratory Biomarkers. Appl Sci. 2022;12(23):12180. doi:10.3390/app122312180
   Google Scholar
• Mertoglu C, Huyut MT, Arslan Y, Ceylan Y, Coban TA. How do routine laboratory tests change in coronavirus disease 2019? Scand J Clin Lab Invest. 2021;81:24–33. doi:10.1080/00365513.2020.1855470
   PubMed Web of Science ®Google Scholar
• Huyut MT, Velichko A. Diagnosis and Prognosis of COVID-19 Disease Using Routine Blood Values and LogNNet Neural Network. Multidisciplinary Digital Publishing Institute. 2022;22:4820.
   Google Scholar
• Huyut MT. Automatic Detection of Severely and Mildly Infected COVID-19 Patients with Supervised Machine Learning Models. IRBM. 2022;44(1). doi:10.1016/j.irbm.2022.05.006
   Web of Science ®Google Scholar
• Huyut MT, İlkbahar F. The effectiveness of blood routine parameters and some biomarkers as a potential diagnostic tool in the diagnosis and prognosis of Covid-19 disease. Int Immunopharmacol. 2021;2:98.
   Google Scholar
• Wang L, Lv Q, Zhang X, et al. The utility of MEWS for predicting the mortality in the elderly adults with COVID-19: a retrospective cohort study with comparison to other predictive clinical scores. PeerJ Inc. 2020;8:562.
   Web of Science ®Google Scholar
• Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Pol Arch Intern Med. 2020; 130: 352–35
   PubMedGoogle Scholar
• Lau CS, Hoo SP, Koh JMJ, Phua SK, Aw TC. Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms. J Virol Methods. 2021;296:114224.
   PubMed Web of Science ®Google Scholar
• Alinity c CRP Vario WR Cal Kit. Available from: https://www.e-abbott.com/icq-crp-cal-high-sense.html. Accessed May 9, 2023.
   Google Scholar
• Erdogan A, Can FE, Gönüllü H. Evaluation of the prognostic role of NLR, LMR, PLR, and LCR ratio in COVID-19 patients. J Med Virol. 2021;93:5555–5559. doi:10.1002/jmv.27097
   PubMed Web of Science ®Google Scholar
• Tyurin AV. Correlation of the Imbalance in the Circulating Lymphocyte Subsets With C-Reactive Protein and Cardio-Metabolic Conditions in Patients With COVID-19. Frontiers Media. 2022;13:1.
   Google Scholar
• Ahsan M, Kurpad K, Mehta H, et al. The prognostic significance of lymphocyte-to-crp ratio (Lcr) in patients with COVID-19. Crit Care Med. 2021;49:56. doi:10.1097/01.ccm.0000726452.58093.aa
   Web of Science ®Google Scholar
• Zhang JN, Gao Y, Wang XT, et al. Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.957407
   Web of Science ®Google Scholar
• Khan MUF, Ali BR, Mohammed HQ, et al. Serum level estimation of some biomarkers in diabetic and non-diabetic COVID-19 infected patients. Appl Nanosci. 2022;1–8.
   Web of Science ®Google Scholar
• Montesarchio V, Parella R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. BMJ Specialist J. 2020;8:e001089.
   Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327–331.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848. doi:10.1007/s00134-020-05991-x
   PubMed Web of Science ®Google Scholar
• Basina B, Bielosludtseva K, Pertseva T, Kirieieva T, Krykhtina M, Kravchenko N. C-reactive protein (CRP) at admission: is it really useful in COVID-19 pneumonia? Eur Respir Soc. 2021;58:PA654.
   Web of Science ®Google Scholar
• Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;1:127.
   Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi:10.1038/s41586-020-2008-3
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422. doi:10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Tarique M, Suhail M, Naz H, et al. Where do T cell subsets stand in SARS-CoV-2 infection: an update. Front Cell Infect Microbiol. 2022;12:1110. doi:10.3389/fcimb.2022.964265
   Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7:998. doi:10.1093/nsr/nwaa041
   PubMed Web of Science ®Google Scholar
• Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obesity Rev. 2020;21. doi:10.1111/obr.13128
   PubMed Web of Science ®Google Scholar
• Stefan N, Sippel K, Heni M, et al. Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: the LEOSS Registry. Front Med. 2022;9. doi:10.3389/fmed.2022.875430
   Web of Science ®Google Scholar
• Gupta S, Hayek SS, Wang W, et al. Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180:1436–1447. doi:10.1001/jamainternmed.2020.3596
   PubMed Web of Science ®Google Scholar
• Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–307. doi:10.1016/j.ijid.2020.04.061
   PubMed Web of Science ®Google Scholar
• Eissa M, Shaarawy S, Abdellateif MS. The role of different inflammatory indices in the diagnosis of covid-19. Int J Gen Med. 2021;14:7843–7853. doi:10.2147/IJGM.S337488
   PubMed Web of Science ®Google Scholar
• Bhowmik KK, Barek MA, Aziz MA, Islam MS. A systematic review and meta-analysis of abnormalities in hematological and biochemical markers among Bangladeshi COVID-19 cases. Health Sci Rep. 2022;5. doi:10.1002/hsr2.728
   Google Scholar
• Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349:29–35. doi:10.1097/MAJ.0000000000000332
   PubMed Web of Science ®Google Scholar
• Toori KU, Qureshi MA, Chaudhry A. Lymphopenia: a useful predictor of COVID-19 disease severity and mortality. Pak J Med Sci. 2021;37:1984. doi:10.12669/pjms.37.7.4085
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol Lett. 2020;225:31–32. doi:10.1016/j.imlet.2020.06.013
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11. doi:10.3389/fimmu.2020.00827
   Web of Science ®Google Scholar
• Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8. doi:10.1186/s40560-020-00453-4
   Web of Science ®Google Scholar
• Asghar MS, Khan NA, Haider Kazmi SJ, et al. Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis. J Community Hosp Intern Med Perspect. 2020;10:514–520. doi:10.1080/20009666.2020.1816276
   PubMed Web of Science ®Google Scholar
• Adab P, Haroon S, O’Hara ME, Jordan RE. Comorbidities and covid-19. BMJ. 2022;377.
   Google Scholar
• Banai A, Szekely Y, Lupu L, et al. QT Interval Prolongation Is a Novel Predictor of 1-Year Mortality in Patients With COVID-19 Infection. Front Cardiovasc Med. 2022;9. doi:10.3389/fcvm.2022.869089
   PubMed Web of Science ®Google Scholar
• Isakadze N, Engels MC, Beer D, et al. C-reactive Protein Elevation Is Associated With QTc Interval Prolongation in Patients Hospitalized With COVID-19. Front Cardiovasc Med. 2022;9:1303. doi:10.3389/fcvm.2022.866146
   Web of Science ®Google Scholar
• Lazzerini PE, Accioli R, Acampa M, et al. Interleukin-6 Elevation Is a Key Pathogenic Factor Underlying COVID-19-Associated Heart Rate-Corrected QT Interval Prolongation. Front Cardiovasc Med. 2022;9. doi:10.3389/fcvm.2022.893681
   Web of Science ®Google Scholar
• Gulletta S, Della Bella P, Pannone L, et al. QTc interval prolongation, inflammation, and mortality in patients with COVID-19. J Int Cardiac Electrophysiol. 2022;63:441–448. doi:10.1007/s10840-021-01033-8
   PubMed Web of Science ®Google Scholar
• Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol. 2021;12:263. doi:10.3389/fimmu.2021.613422
   Web of Science ®Google Scholar